Forest Laboratories, LLC 4

Accession 0001209191-14-046081

CIK 0000038074operating

View on SEC.gov Company Profile

Filed

Jul 2, 8:00 PM ET

Accepted

Jul 3, 5:18 PM ET

Size

55.2 KB

Accession

0001209191-14-046081

Insider Transaction Report

Form 4

Period: 2014-07-01

Forest Laboratories, LLCFRX

Taglietti Marco

Exec. VP-Chief Medical Officer

Transactions

Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−3,108→ 0 total
Exercise: $32.17Exp: 2020-12-05→ Common Stock (3,108 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−1→ 0 total
Exercise: $30.00Exp: 2021-12-04→ Common Stock (1 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−56,892→ 0 total
Exercise: $32.17Exp: 2020-12-05→ Common Stock (56,892 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−62,099→ 0 total
Exercise: $30.00Exp: 2021-12-04→ Common Stock (62,099 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−55,320→ 0 total
Exercise: $37.88Exp: 2023-05-20→ Common Stock (55,320 underlying)
Award
Performance Stock Units
2014-07-01+27,700→ 27,700 total
Exercise: $0.00→ Common Stock (27,700 underlying)
Award
Performance Stock Units
2014-07-01+15,930→ 15,930 total
Exercise: $0.00→ Common Stock (15,930 underlying)
Disposition to Issuer
Restricted Stock
2014-07-01−31,334→ 0 total
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−12,535→ 0 total
Exercise: $39.88Exp: 2017-08-12→ Common Stock (12,535 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−47,465→ 0 total
Exercise: $39.88Exp: 2017-08-12→ Common Stock (47,465 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−4,145→ 0 total
Exercise: $24.12Exp: 2018-12-08→ Common Stock (4,145 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−3,198→ 0 total
Exercise: $31.27Exp: 2019-12-06→ Common Stock (3,198 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−36,802→ 0 total
Exercise: $31.27Exp: 2019-12-06→ Common Stock (36,802 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−2,938→ 0 total
Exercise: $34.04Exp: 2022-05-06→ Common Stock (2,938 underlying)
Disposition to IssuerSwap
Stock Option (Right to Buy)
2014-07-01−2,640→ 0 total
Exercise: $37.88Exp: 2023-05-20→ Common Stock (2,640 underlying)
Disposition to Issuer
Common Stock
2014-07-01−62,410→ 0 total
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−20,855→ 0 total
Exercise: $24.12Exp: 2018-12-08→ Common Stock (20,855 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2014-07-01−25,562→ 0 total
Exercise: $34.04Exp: 2022-05-06→ Common Stock (25,562 underlying)
Disposition to Issuer
Performance Stock Units
2014-07-01−27,700→ 0 total
Exercise: $0.00→ Common Stock (27,700 underlying)
Disposition to Issuer
Performance Stock Units
2014-07-01−15,930→ 0 total
Exercise: $0.00→ Common Stock (15,930 underlying)

Footnotes (19)

[F1]Each share of common stock was disposed of pursuant to the Merger Agreement, dated as of February 17, 2014 (the "Merger Agreement"), by and among the issuer and Actavis plc ("Actavis"), Tango US Holdings Inc., Tango Merger Sub 1 LLC, and Tango Merger Sub 2 LLC in exchange for either (A) $26.04 in cash plus 0.3306 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger or (B) $25.67 in cash plus 0.332623 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger, depending on the consideration election made by the reporting person and the consideration election proration procedures set forth in the Merger Agreement.
[F10]The options, 27,000 of which are currently exercisable, 9,000 of which vest on December 6, 2014, and 20,892 of which vest on December 6, 2015, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F11]The option, which vests on December 5, 2015, was assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F12]The options, 31,050 of which are currently exercisable, 15,525 of which vest on December 5, 2014, and 15,524 of which vest on December 5, 2015, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F13]The options, which vest on May 7, 2016, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F14]The options, 14,250 of which are currently exercisable, 7,125 of which vest on May 7, 2015, and 4,187 of which vest on May 7, 2016, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F15]The options, which vest on May 21, 2017, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F16]The options, 14,490 of which are currently exercisable, 14,490 of which vest on May 21, 2015, 14,490 of which vest on May 21, 2016, and 11,850 of which vest on May 21, 2017, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F17]The performance conditions with respect to the issuer performance stock unit award were deemed to be earned based on target performance as of the effective time of the transaction, and the performance stock unit award (as so earned) will vest on April 1, 2015, subject to the reporting person's continued employment through such date and also to acceleration in the event of certain terminations of employment.
[F18]The performance conditions with respect to the issuer performance stock unit award were deemed to be earned based on target performance as of the effective time of the transaction, and the performance stock unit award (as so earned) will vest on April 1, 2016, subject to the reporting person's continued employment through such date and also to acceleration in the event of certain terminations of employment.
[F19]Each outstanding performance stock unit award (as deemed earned pursuant to the Merger Agreement) was assumed by Actavis pursuant to the Merger Agreement and replaced with an Actavis restricted stock unit award covering 0.4723 Actavis ordinary shares having a market value of $224.00 per share on the effective date of the merger for each issuer share underlying the performance stock unit award.
[F2]Outstanding restricted stock awards were assumed by Actavis pursuant to the Merger Agreement and replaced with an Actavis restricted stock unit award covering 0.4723 Actavis ordinary shares having a market value of $224 per share on the effective date of the merger for each issuer share underlying the restricted stock award.
[F3]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F4]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F5]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F6]The options, which are currently exercisable, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F7]The options, which vest on December 7, 2014, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F8]The options, 24,000 of which are currently exercisable and 12,802 of which vest on December 7, 2014, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.
[F9]The options, which vest on December 6, 2015, were assumed by Actavis pursuant to the Merger Agreement and replaced with an option to purchase a number of whole Actavis ordinary shares equal to the product of (i) the number of shares of issuer common stock subject to such issuer option multiplied by (ii) 0.4723, at an exercise price per share equal to the quotient obtained by dividing (x) the exercise price per share of the issuer option by (y) 0.4723.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Forest Laboratories, LLC

CIK 0000038074

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0000038074

Filing Metadata

Form type: 4
Filed: Jul 2, 8:00 PM ET
Accepted: Jul 3, 5:18 PM ET
Size: 55.2 KB

View on SEC.gov